APTORUM GROUP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.71 USD | +2.39% |
|
+4.67% | +92.35% |
| Apr. 30 | Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 06 | Top Midday Gainers | MT |
Presenter SpeechUnknown Attendee (Attendees)Next, we have Aptorum Group, a pharmaceutical comp...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aptorum Group Limited is United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's business segments include Therapeutics and Non-Therapeutics. Therapeutics segment is engaged in developing various drug molecules and certain technologies for treatment of human disease conditions. Two of the Companyâs lead projects, ALS-4 and SACT-1, target infectious disease and cancer, including orphan oncology indications. Non-Therapeutics segment encompasses three businesses: diagnostics projects including PathsDx Test, natural supplements including NativusWell, and AML Clinic. PathsDx Test is a novel molecular-based rapid pathogen identification and detection diagnostics technology, which is under co-development with A*STAR.
Sector
Pharmaceuticals
Calendar
2024-09-09
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +92.35% | 25.17M | |
| +31.37% | 588B | |
| -2.90% | 364B | |
| +20.40% | 326B | |
| +5.38% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.72% | 167B | |
| +0.16% | 161B |
- Stock Market
- Equities
- APM Stock
- News Aptorum Group Limited
- Transcript : Aptorum Group Limited Presents at LD Micro 500 Virtual Investor Conference, Sep-01-2020 09
